Given the potent role of PLK1 in sustaining tumor growth [32, 35] and mediating KRASG12Ci resistance, PLK1i would serve as both a pharmacological means to interrogate the dependence on PLK1 kinase activity and a promising point for a potential drug combination campaign. This evidence concerns the gene PLK1 and neoplasm.